Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer

Bibliography

• American Cancer Society. Global cancer facts and figures. 2008. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf [Last accessed 29 April 2015]
   Google Scholar
• American Cancer Society. Prostate cancer. 2015. Available from: http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics [Last accessed 29 April 2015]
   Google Scholar
• Cancer Research UK. Prostate cancer. 2014. Available from: http://publications.cancerresearchuk.org/downloads/Product/CS_KF_PROSTATE.pdf [Last accessed 29 April 2015]
   Google Scholar
• Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol 2008;10:111-19
   PubMedGoogle Scholar
• Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin 2009;59:264-73
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Lifetime risk of developing or dying from cancer. 2014. Available from: http://www.cancer.org/cancer/cancerbasics/lifetime-probability-of-developing-or-dying-from-cancer [Last accessed 29 April 2015]
   Google Scholar
• Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9-12
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. 2015. Available from: http://uroweb.org/guideline/prostate-cancer/ [Last accessed 29 April 2015]
   Google Scholar
• Shore ND, Abrahamsson PA, Anderson J, et al. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis 2013;16:7-15
   PubMed Web of Science ®Google Scholar
• Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895-903
   PubMed Web of Science ®Google Scholar
• Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314-25
   PubMed Web of Science ®Google Scholar
• Ahmadi H, Daneshmand S. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Patient Relat Outcome Meas 2014;5:63-70
   PubMedGoogle Scholar
• Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: A meta-analysis. Eur Urol 2014
   PubMed Web of Science ®Google Scholar
• Smith MR, Klotz L, van der Meulen E, et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011;186:1835-42
   PubMed Web of Science ®Google Scholar
• Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990;144:1479-80
   PubMed Web of Science ®Google Scholar
• Pickles T, Hamm J, Morris WJ, et al. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter? BJU Int 2012;110:E500-7
   PubMedGoogle Scholar
• Dixit VD, Yang LH, Udhayakumar V, Sridaran R. GnRH alters the T helper cytokine balance in the pregnant rat. Biol Reprod 2003;68(6):2215-21
   PubMed Web of Science ®Google Scholar
• Shore ND. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol 2013;5:11-24
   PubMedGoogle Scholar
• Broqua P, Riviere P, Conn P, et al. Pharmacological profile of a new, potent, and long acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002;301:95-102
   PubMed Web of Science ®Google Scholar
• Koechling W, Hjortkjaer R, Tankó L. Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol 2010;70:580-7
   PubMed Web of Science ®Google Scholar
• Matsuo H, Baba Y, Nair RM, et al. Structure of the porcine LH-and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971;43:1334-9
   PubMed Web of Science ®Google Scholar
• Schally AV, Coy DH. Stimulatory and inhibitory analogs of luteinizing hormone releasing hormone (LHRH). Adv Exp Med Biol 1977;87:99-121
   PubMedGoogle Scholar
• Vilchez-Martinez JA, Pedroza E, Coy DH, et al. Prolonged release of LH and FSH and depletion of pituitary gonadotropin content after administration of [D-Leu6, desGly-NH2(10)]-LH-RH ethylamide. Proc Soc Exp Biol Med 1977;154:427-30
   PubMed Web of Science ®Google Scholar
• Sonesson A, Koechling W, Stalewski J, et al. Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey. Drug Metab Dispos 2011;39:1895-903
   PubMed Web of Science ®Google Scholar
• Jiang G, Stalewski J, Galyean R, et al. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001;44:453-67
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, van der Meulen E, Persson B-E. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol 2011;3:127-40
   PubMedGoogle Scholar
• Labrie F, Bélanger A, Luu-The V, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005;26:361-79
   PubMed Web of Science ®Google Scholar
• Bhasin S, Berman N, Swerdloff RS. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment. J Androl 1994;15:386-91
   PubMed Web of Science ®Google Scholar
• Varenhorst E, Wallentin L, Carlström K. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand J Urol Nephrol 1982;16:31-6
   PubMed Web of Science ®Google Scholar
• Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531-8
   PubMed Web of Science ®Google Scholar
• Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011;186:889-97
   PubMed Web of Science ®Google Scholar
• Tornøe CW, Agersø H, Nielsen HA, et al. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix. Pharm Res 2004;21:574-84
   PubMed Web of Science ®Google Scholar
• Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs 2009;69:1967-76
   PubMed Web of Science ®Google Scholar
• Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther 2009;31.2312-31
   PubMed Web of Science ®Google Scholar
• Firmagon® (degarelix for injection) european summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000986/WC500023252.pdf [Last accessed 29 April 2015]
   Google Scholar
• Firmagon® (degarelix for injection) US Prescribing Information. Available from: http://www.firmagon.us/full_pi.pdf [Last accessed 29 April 2015]
   Google Scholar
• Sonesson A, Rasmussen BB. In vitro and in vivo human metabolism of degarelix, a gonadotropin-releasing hormone receptor blocker. Drug Metab Dispos 2013;41:1339-46
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase II dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805-13
   PubMed Web of Science ®Google Scholar
• Gittelman M, Pommerville PJ, Persson BE, et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008;180:1986-92
   PubMed Web of Science ®Google Scholar
• Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010;57:836-42
   PubMed Web of Science ®Google Scholar
• Crawford ED, Rove KO, Schally AV, et al. The role of the FSH system in the development and progression of prostate cancer. Am J Hemat Oncol 2014;10(6):5-13
   Google Scholar
• Rick FG, Schally AV. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urol Oncol 2015;33(6):270-4
   PubMed Web of Science ®Google Scholar
• Ide H, Terado Y, Sakamaki K, et al. Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer. Prostate Int 2013;1(3):109-12
   PubMedGoogle Scholar
• Mariani S, Salvatori L, Basciani S, et al. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 2006;175(6):2072-7
   PubMed Web of Science ®Google Scholar
• Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010;363:1621-30
   PubMed Web of Science ®Google Scholar
• Hopmans SN, Duivenvoorden WC, Werstuck GH, et al. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol 2014;32:1126-34
   PubMed Web of Science ®Google Scholar